[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529070":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":24,"responsibleParty":33,"collaborators":24,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":24,"eligibilityCriteria":42,"healthyVolunteers":39,"sex":43,"minAge":24,"maxAge":24,"enrollmentInfo":44,"targetDuration":24,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":24,"overallStatus":53,"whyStopped":24,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":24},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Amiodarone as comparison","ACTIVE_COMPARATOR","50 patients \\>\\>Amiodarone +other treatmen",[13],"Drug: Eplerenone",{"label":15,"type":16,"description":11,"interventionNames":17},"Eplerenone plus amiodarone","EXPERIMENTAL",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Eplerenone","Amiodarone vs eplerenone in AF",[9,15],null,[26,31],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Walid Abdellah","CONTACT","01158931616","walidshehata573@gmail.com",{"name":32,"role":28,"phone":24,"phoneExt":24,"email":24},"Hatem Helmy",{"type":34,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Walid Shehata Ahmed abdellah","Resident","100529070","phase-4-role-of-eplerenone-in-reducing-recurrence-of-atrial-fibrillation-in-patient-with-structural-heart-disease-100529070",false,"NCT06168994","Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease","Inclusion Criteria:\n\n\\- paroxysmal AF who reverted to sinus rhythm either medically or electrically without appropriate secondary cause of primary AF\n\n•AF attack should be documented with ECG\n\nExclusion Criteria:\n\n* 1-patients are currently on eplerenone or spironolactone 2-hyperkalemia 3-impaired renal function(if CrCl \\\u003C50ml\u002Fmin or serum creatinine\\>2 mg\u002Fdl) 4-patient on beta blocker and calcium channel blocker (non- dihydropyridine) 5-prosthetic valve 6-severe mitral stenosis 7-thyroid dysfunction 8-WPW 9-severe liver disease 10-persistent or permanent AF 11-pregnancy or breast feeding 12-LV EF\\\u003C50% 13-known hypersensitivity or drug reaction to amiodarone 14-acute coronary syndrome 15-refusal of consent","ALL",{"count":45,"type":46},100,"ESTIMATED","INTERVENTIONAL",[49],"PHASE4","The aim of this study is to study synergistic effect of eplerenone as Selective aldosterone receptor antagonist with amiodarone compared with amiodarone only in reducing recurrence of atrial fibrillation in patient with structural heart disease",[52],"Paroxysmal Atrial Fibrillation","NOT_YET_RECRUITING","2023-12-05",{"date":56,"type":57},"2023-12-13","ACTUAL",{"date":59,"type":46},"2024-02-01",{"date":61,"type":46},"2027-05-20",{"name":5,"class":6}]